merged_engineered-virus-steals-proteins-from-hiv.txt
<question_number>1</question_number>
<answer>TIPs potentially require just one permanent shot, while lenacapavir requires twice-yearly shots that people in poor countries might struggle to keep up with</answer>

<question_number>2</question_number>
<answer>It might make it harder for people to transmit H.I.V. to others</answer>

<question_number>3</question_number>
<answer>TIPs can potentially spread to others who haven't consented to the treatment</answer>

<question_number>4</question_number>
<answer>N/A</answer>
<other>The article doesn't explicitly compare the mechanism advantages of TIPs over protease inhibitors</other>

<question_number>5</question_number>
<answer>N/A</answer>
<other>While ethical concerns about permanence and potential transmission to others are mentioned, the article doesn't specifically identify which would be the most significant challenge for clinical trials</other>

<question_number>6</question_number>
<answer>TIPs are engineered to do a better job of entering viral shells, resulting in infected cells releasing three times more TIPs than H.I.V. viruses</answer>

<question_number>7</question_number>
<answer>If unexpected side effects occur, it may not be possible to remove TIPs from the body</answer>

<question_number>8</question_number>
<answer>N/A</answer>
<other>While Dr. Leeks states it's "a universal approach" and that "other viruses might also be vulnerable to the same strategy," he doesn't explicitly explain why it's universal</other>

<question_number>9</question_number>
<answer>Doctors cannot receive consent from anyone who might be secondarily infected with TIPs</answer>

<question_number>10</question_number>
<answer>TIPs work by competing with H.I.V. for resources within cells and outcompeting it, while traditional drugs like protease inhibitors directly block specific viral proteins</answer>